

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/937,192	09/21/2001	Neal Rosen	MSK.P-038	6277
21121 7	7590 09/12/2002			
OPPEDAHL AND LARSON LLP P O BOX 5068 DILLON, CO 80435-5068			EXAMINER	
			KIFLE, BRUCK	
			ART UNIT	PAPER NUMBER
			1624) i
			DATE MAILED: 09/12/2002	()

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/937,192

Applicant(s)

Rosen et al

Examine

Bruck Kifle, Ph.D.

Art Unit 1624



	The MAILING DATE of this communication appears on	the cover she	et with:	the correspondence address		
	for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE THE MAILING DATE OF THIS COMMUNICATION.						
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.						
- If the p - If NO p - Failure - Any re	period for reply specified above is less than thirty (30) days, a reply within the stoperiod for reply is specified above, the maximum statutory period will apply and voto reply within the set or extended period for reply will, by statute, cause the apply received by the Office later than three months after the mailing date of this capatent term adjustment. See 37 CFR 1.704(b).	will expire SIX (6) N pplication to becom	MONTHS ne ABAND	from the mailing date of this communication. DONED (35 U.S.C. § 133).		
Status						
1) 💢	Responsive to communication(s) filed on Jul 22, 2002	2		<u> </u>		
2a) □	This action is FINAL . 2b) X This action	ı is non-final.				
3) 🗆	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.					
	tion of Claims					
4) 💢	Claim(s) 3, 4, 6, and 9-34			is/are pending in the application.		
4	a) Of the above, claim(s)			is/are withdrawn from consideration.		
5) 🗆	Claim(s)			is/are allowed.		
6) 💢	Claim(s) 3, 4, 6, and 9-34			is/are rejected.		
7) 🗌	Claim(s)			is/are objected to.		
8) 🗆	Claims	are	subjec	t to restriction and/or election requirement.		
Applica	tion Papers					
9) 🗌	The specification is objected to by the Examiner.					
10)	10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.					
	Applicant may not request that any objection to the draw	ving(s) be held	d in abe	eyance. See 37 CFR 1.85(a).		
11)□	The proposed drawing correction filed on	is:	a) 🗌	approved b) \square disapproved by the Examiner.		
	If approved, corrected drawings are required in reply to the	his Office acti	ion.			
12) The oath or declaration is objected to by the Examiner.						
	under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ∟	☐ All b)☐ Some* c)☐ None of:					
	1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No					
	3. Copies of the certified copies of the priority docu application from the International Bureau ((PCT Rule 17	7.2(a)).	•		
_	ee the attached detailed Office action for a list of the ce					
14)	Acknowledgement is made of a claim for domestic price.					
a) The translation of the foreign language provisional application has been received. 15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachme		ority under 3	o u.s.	C. 33 120 and/or 121.		
		Interview Sum	mary (PT	O-413) Paper No(s)		
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) Notice of Informal Patent Application (PTO-152)						
3) N Information Disclosure Statement(s) (PTO-1449) Paper No(s). 6 and 9 6) Other:						

Application/Control Number: 09/937,192

Art Unit: 1624

Applicant's amendments and remarks filed 7/22/02 have been received and reviewed. Claims 3, 4, 6 and 9-34 are now pending in this application.

Claim Rejections - 35 USC § 112

Claims 3, 4, 6 and 9-34 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The scope of the ansamycin antibiotic is unclear. In the specification, page 1, lines 26-27, only GM and HA are said to be ansamycin antibiotics. A clarification is required as to what else is intended.

Claims 3, 4, 6 and 9-30 are again rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Undue experimentation is required to use compounds of the instant claims to treat cancers generally or those which overexpress a HER-family kinase. The specification does not provide enablement for the treatment of cancer generally. The basis of this rejection is the same as given in the previous office action and is incorporated herein fully by reference. Note, In re Buting 163 USPQ 689 establishes that even clinical tests showing that a compound found to be useful in the treatment of two types of cancers was not sufficient for a much broader range.

Page 2

Application/Control Number: 09/937,192 Page 3

Art Unit: 1624

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruck Kifle whose telephone number is (703) 305-4484.

The fax phone number for this Group is (703) 308-4556 or (703) 305-3592. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

September 11, 2002

Bruck Kiflé Primary Examiner Art Unit 1624